Condition: Diabetes Mellitus, Type 2 · Obesity · Overweight · Sponsor: Eli Lilly and Company
The main purpose of this study is to measure the safety and efficacy of tirzepatide in adult participants in India who have type 2 diabetes or who have obesity or overweight without type 2 diabetes. Participation in the study will last about 46 weeks.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| B. J. Medical College & Civil Hospital | Ahmedabad, India | Recruiting |
| V.S. General Hospital | Ahmedabad, India | Not Yet Recruiting |
| Gujarat Endocrine Center | Ahmedabad, India | Recruiting |
| Jawahar Lal Nehru Medical College | Ajmer, India | Not Yet Recruiting |
| Motilal Nehru Medical College Hospital | Allahābād, India | Recruiting |
| Lifecare Hospital and Research Centre | Bengaluru, India | Recruiting |
| AIIMS, Bhubaneshwar | Bhubaneswar, India | Not Yet Recruiting |
| Sri Ramachandra MedicaL College & Research Institute | Chennai, India | Recruiting |
| Kovai Diabetes Speciality Center and Hospital | Coimbatore, India | Recruiting |
| Apollo Excelcare Hospital | Guwahati, India | Recruiting |
| Osmania Medical College & Hospital | Hyderabad, India | Recruiting |
| Eternal Heart Care Center and Research Institute | Jaipur, India | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07438444